EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women






Journal of Clinical Endocrinology and Metabolism 78(6): 1312-1319

Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women

Modifications were made to a commercially available human (h) GH chemiluminescence assay (Nichols Luma Tag hGH assay), which improved its sensitivity to 0.002 micrograms/L. The results of this assay had a high correlation with those of the Nichols hGH immunoradiometric assay (IRMA; r = 0.91; P < 0.001). The addition of recombinant hGH-binding protein (0.1-10 nmol/L) to standards and serum samples caused a dose-responsive reduction in measured GH in both the chemiluminescence assay and the IRMA; at physiological concentrations of hGH-binding protein, a 10-20% reduction was observed. Fifteen normal young adults (nine men and six women) underwent a standard 100-g oral glucose tolerance test, and plasma GH was measured from 30 min before until 5 h after glucose ingestion. GH was measurable in all samples with the chemiluminescence assay, but fell below the sensitivity of the IRMA in 59% of the samples. There was no difference between baseline or peak glucose levels in male and female subjects, but serum GH concentrations (mean +/- SD) measured by the enhanced sensitivity chemiluminescence assay were lower in male than female subjects at both baseline (0.12 +/- 0.08 vs. 2.3 +/- 2.3 micrograms/L; P < 0.01) and the postglucose GH nadir (0.029 +/- 0.014 vs. 0.25 +/- 0.23 micrograms/L; P < 0.01). The high correlation between baseline and nadir GH (r = 0.82; P < 0.001) and the equivalent fractional decline in mean GH levels in men and women after glucose administration (67 +/- 17% vs. 84 +/- 8%; P = 0.06) suggest that the lower GH levels in men after glucose treatment are due to lower baseline values and not to a greater suppressive effect of glucose.


Accession: 045967251

PMID: 8200931

DOI: 10.1210/jcem.78.6.8200931



Related references

Chapman, I.M.; Hartman, M.L.; Straume, M.; Johnson, M.L.; Veldhuis, J.D.; Thorner, M.O., 1994: Enhanced sensitivity growth hormone chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. Modifications were made to a commercially available human (h) GH chemiluminescence assay (Nichols Luma Tag hGH assay), which improved its sensitivity to 0.002 mu-g/L. The results of this assay had a high correlation with those of the Nichols hGH i...

Ribeiro-Oliveira, Aônio.; Faje, A.; Barkan, A., 2012: Postglucose growth hormone nadir and insulin-like growth factor-1 in naïve-active acromegalic patients: do these parameters always correlate?. Arquivos Brasileiros de Endocrinologia E Metabologia 55(7): 494-497

Leidy, John W.Jr, 1996: Enhanced sensitivity of a two-site acridinium ester based immunochemiluminometric assay for rat growth hormone-releasing hormone using simple modifications in assay procedure. Using six simple modifications in assay procedure, the sensitivity of a two-site immunochemiluminometric assay for rat growth hormone-releasing hormone was enhanced 9.5-fold from 35 fg/tube to 3.7 fg/tube, improving performance for physiologic exp...

Leidy, J.W., 1994: High sensitivity two-site immunoradiometric and immunochemiluminometric assays for rat growth hormone-releasing hormone. Development of an acridinium ester based chemiluminescence assay for the avidin-coated bead system. High sensitivity two-site immunoradiometric and immunochemiluminometric assays were developed for the direct measurement of rat GHRH in perifusate of hypothalamic fragments and in hypophysial portal plasma. A solid phase immunoradiometric assay wa...

Leidy, John, W.Jr, 1994: High sensitivity two-site immunoradiometric and immunochemiluminometric assays for rat growth hormone-releasing hormone. Development of an acridinium ester based chemiluminescence assay for the avidin-coated bead system. High sensitivity two-site immunoradiometric and immunochemiluminometric assays were developed for the direct measurement of rat GHRH in perifusate of hypothalamic fragments and in hypophysial portal plasma. A solid phase immunoradiometric assay wa...

Nindl, B.C.; Gotshalk, L.A.; Marx, J.O.; Hymer, W.C.; Kraemer, W.J., 1999: Growth hormone concentrations in men and women after resistance exercise are assay dependent. Medicine & Science in Sports & Exercise 31(5 SUPPL ): S229, May

Nindl, B.C.; Bush, J.A.; Kim, S.K.; Dohi, K.; Hymer, W.C.; Kraemer, W.J., 1999: Growth hormone concentrations in women Effects of exercise, menstrual status and assay method. FASEB Journal 13(4 PART 1): A80, March 12

Ronchi, C.L.; Arosio, M.; Rizzo, E.; Lania, A.G.; Beck-Peccoz, P.; Spada, A., 2007: Adequacy of current postglucose GH nadir limit (< 1 microg/l) to define long-lasting remission of acromegalic disease. Some authors proposed to lower the present postglucose GH nadir cut-off (i.e. < 1 microg/l) to that obtained in healthy subjects to establish remission of acromegaly. The aim of the study was to correlate GH nadir with hormonal and metabolic pa...

Evans, W.S.; Borges, J.L.; Vance, M.L.; Kaiser, D.L.; Rogol, A.D.; Furlanetto, R.; Rivier, J.; Vale, W.; Thorner, M.O., 1984: Effects of human pancreatic growth hormone-releasing factor-40 on serum growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and somatomedin-C concentrations in normal women throughout the menstrual cycle. Human pancreatic tumor GH-releasing factor-40 (hpGRF-40) selectively stimulates GH secretion in normal men and in some adults with GH deficiency. To study its effects in women, we administered hpGRF-40 (3.33 micrograms/kg) or an equivalent volume...

Willaschek, C.; Meint, S.; Rager, K.; Buchhorn, R., 2016: Modified Clonidine Testing for Growth Hormone Stimulation Reveals α2-Adrenoreceptor Sub Sensitivity in Children with Idiopathic Growth Hormone Deficiency. The association between short stature and increased risk of ischemic heart disease has been subject to studies for decades. The recent discussion of cardiovascular risk during growth hormone therapy has given new importance to this question. We ha...